Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Guided Therapeutics (GTHP) over the last 15 years, with Q3 2025 value amounting to $204000.0.

  • Guided Therapeutics' Change in Accured Expenses rose 20909.09% to $204000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $687000.0, marking a year-over-year increase of 2224.2%. This contributed to the annual value of $545000.0 for FY2024, which is 116744.19% up from last year.
  • Guided Therapeutics' Change in Accured Expenses amounted to $204000.0 in Q3 2025, which was up 20909.09% from $221000.0 recorded in Q2 2025.
  • Guided Therapeutics' Change in Accured Expenses' 5-year high stood at $571000.0 during Q4 2021, with a 5-year trough of -$450000.0 in Q3 2021.
  • For the 5-year period, Guided Therapeutics' Change in Accured Expenses averaged around $72473.7, with its median value being $66000.0 (2024).
  • As far as peak fluctuations go, Guided Therapeutics' Change in Accured Expenses plummeted by 45433.07% in 2021, and later skyrocketed by 200952.38% in 2024.
  • Over the past 5 years, Guided Therapeutics' Change in Accured Expenses (Quarter) stood at $571000.0 in 2021, then plummeted by 77.41% to $129000.0 in 2022, then skyrocketed by 34.11% to $173000.0 in 2023, then fell by 9.83% to $156000.0 in 2024, then surged by 30.77% to $204000.0 in 2025.
  • Its last three reported values are $204000.0 in Q3 2025, $221000.0 for Q2 2025, and $106000.0 during Q1 2025.